All In Biotech

NDA 201739 · Kaleo INC

Auvi-Q

Epinephrine · Intramuscular, Subcutaneous · alpha-Adrenergic Agonist; beta-Adrenergic Agonist; Catecholamine

Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Aug 10, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,347

454 Phase 3, 232 recruiting

FAERS reports

43,337

26,523 serious, 3,554 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2026.

AUVI-Q is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 7.5 kg or greater. AUVI-Q is a non-selective alpha and beta-adrenergic receptor agonist indicated for the emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 7.5 kg or greater. ( 1 )

Mechanism: Epinephrine acts on both alpha and beta-adrenergic receptors. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • AUVI-Q · EPINEPHRINE EQ 0.3MG/DELIVERY · SOLUTION, INTRAMUSCULAR, SUBCUTANEOUS · Prescription · TE BX
  • AUVI-Q · EPINEPHRINE EQ 0.15MG/DELIVERY · SOLUTION, INTRAMUSCULAR, SUBCUTANEOUS · Prescription · TE BX
  • AUVI-Q · EPINEPHRINE EQ 0.1MG/DELIVERY · SOLUTION, INTRAMUSCULAR, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.

All 2,347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,644
  • headache3,108
  • sinusitis2,928
  • fatigue2,823
  • product dose omission issue2,800
  • pain2,512
  • covid-192,434
  • dyspnoea2,295
  • nausea2,255
  • off label use2,096
  • pneumonia2,078
  • inappropriate schedule of product administration1,794

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004133
2005118
2006136
2007166
2008194
2009269
2010261
2011702
2012425
2013316
2014450
2015693
20161,121
20171,606
20182,536
20193,428
20206,560
20213,969
20223,701
20233,884
20244,553
20254,798
20263,315

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Auvi-Q (Epinephrine)

2024 spending

$713K

Beneficiaries

876

1,035 claims

Per beneficiary

$814

$300.57 per unit

View as table
YearSpending
2020$3,041,274
2021$3,079,706
2022$361,941
2023$719,315
2024$713,329

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,530 on PubMed

Sponsor: Kaleo INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.